Medtronic stock wins new CPT codes for two devices

Medtronic received new Category I CPT codes for its Altaviva and Symplicity Spyral devices, which will take effect in January 2028. This reimbursement milestone follows a strong fiscal Q1 2027 performance, where revenue exceeded expectations, leading management to raise its full-year guidance. Analysts maintain a "Moderate Buy" consensus for Medtronic stock, with an average price target above its current trading price.